Resistance of ER-positive breast cancer to tamoxifen therapy may be driven by APOBEC3B
12/10/2015
Responses to tamoxifen were significantly prolonged by reducing levels of the enzyme APOBEC3B in preclinical models of estrogen receptor-positive breast cancer and significantly shortened by...
Survival and time to surgery, chemotherapy for patients with breast cancer
12/10/2015
The association between survival and the time to surgery and chemotherapy for patients with breast cancer is examined in two original investigations published by JAMA Oncology, along with a related...
Treatment modality is also the most expensive in younger patients, MD Anderson study finds.
ABCSG 18: monoclonal antibody increases disease-free survival in breast cancer
12/10/2015
Giving a monoclonal antibody (denosumab) as adjuvant therapy with aromatase inhibitors in postmenopausal, hormone-receptor-positive breast cancer patients reduces the relapse rate by 18%.
TET proteins help maintain genome integrity
12/10/2015
LJI researchers show that TET-loss of function causes rapid development of malignant cancer.
Racial disparities found in major surgeries at quality-improvement hospitals
12/10/2015
Considerable racial disparities exist in surgical outcomes for black and Hispanic patients undergoing major cancer and non-cancer surgeries in U.S.
Nanotech drug delivery shows promise for improved melanoma treatment
12/10/2015
Researchers have developed a new three-drug delivery system for cancer treatment, especially metastatic melanoma, the deadliest form of skin cancer - and shown that the system may have particular...
Cancer patients' access to minimally invasive hysterectomies remains persistently limited
12/10/2015
Poor and minority women especially affected; low-volume hospitals did the fewest.
Mount Sinai researchers develop tool to determine function of MicroRNAs
12/10/2015
As microRNA biology has been implicated in everything from the development of cancer to virus infections, a new tool developed by scientists at the Icahn School of Medicine at Mount Sinai holds...
SABCS15: Promising phase 1 results lead to phase 2 for ONT-380 in HER2+ breast cancer
12/10/2015
Results of an ongoing phase 1b clinical trial presented at the 2015 San Antonio Breast Cancer Symposium show promise of the experimental anti-cancer agent ONT-380 against metastatic HER2+ breast...